期刊文献+

HBV YMDD外基因变异对核苷类耐药影响的临床研究

The Clinical Study of the Influence on Drug Fast of Nucleotide of outer HBV YMDD Genovariation
下载PDF
导出
摘要 目的:探讨YMDD变异阴性的拉米夫丁耐药患者体内HBV逆转录酶RT区基因是否有变异。方法:采用荧光PCR技术检测拉米夫丁耐药患者HBV YMDD基因情况,用PCR产物直接测序分析RT区基因序列。结果:7份标本均测出YMDD阳性,无发生YMDD变异,2例发生rtL80V/I变异,1例发生rtV173L,其余均无发生RT区基因变异。结论:部分拉米夫丁临床耐药现象的出现可能与HBV RT区基因变异无关。 Objective To probe into the existence of genovariation of RT district in HBV reverse transcriptase in the patients that are drug fast to Lamivudine and negative on YMDD variant. Methods To detect HBV YMDD gene in the patients who are drug fast to Lamivudine by PCR-fluorescent quantitation; to analyze the gene order of RT district through direct sequencing to PCR products. Results There are seven specimens that are YMDD positive, and no YMDD variant. Also, two specimens generate rtL80V/I mutation, and one specimen generates rtV173L mutation. There is no YMDD variant in RT district in the rest of the specimens. Conclusion A part of drug fast of lamivudine isn't likely to be related to genovariation of HBV RT district.
出处 《国际医药卫生导报》 2007年第14期7-11,共5页 International Medicine and Health Guidance News
基金 广州市医药卫生科技项目(2005-YB-208)
关键词 HBV 拉米夫丁 YMDD HBV Lamivudine YMDD
  • 相关文献

参考文献2

二级参考文献24

  • 1Zhang XX, Liu CM, Gong QM, et al. Evolution of wild type and mutants of the YMDD motif of hepatitis B virus polymerase during lamivudine therapy. J Gastroenterolo Hepatolo, 2003, 1353-1357.
  • 2Schalm SW, Heathcote J, Cianciara J, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut, 2000, 46: 562-568.
  • 3Maria Buti, Rafael Esteban. Entecavir, FTC, L-RMAU, LdT and others. J Hepatol, 2003, 39: S139-S142.
  • 4Kirishima T, Okanoue T, Daimon Y, et al. Detection of YMDD mutant using a novel sensitive method in chronic liver disease type B patients before and during lamivudine treatment. J Hepatol, 2002, 37: 259-265
  • 5Liaw YF, Leung N, Guan R, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: an update. J Gastroenterol Hepatol, 2003, 18: 239-245.
  • 6The EASL Jury. EASL international consensus conference on hepatitis B. J Hepatol, 2003, 38: 533-540.
  • 7Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology, 2001, 34: 1225-1241.
  • 8Li LL, Chun TW, Yin ML, et al. Prophylactic lamivudine prevents hepatitis B reactivation and mortality in patients receiving immunosuppression and chemotherapy. Hepatology, 2000, 32(Pt 2): 1183.
  • 9Liaw YF, Sung JJY, Chow WC, et al. Effects of lamivudine on disease progression and development of liver cancer in advanced chronic hepatitis B: a prospective double-blined placebo-controlled clinical trial. Hepatology, 2003, 38(Suppl)1: 262A.
  • 10Fontana RJ. Mangement of patients with decompensated HBV cirrhosis. Seminars in liver disease. 2003 23: 89-100.

共引文献14159

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部